New Sorafenib Derivatives: Synthesis, Antiproliferative Activity Against Tumour Cell Lines and Antimetabolic Evaluation

Sorafenib is a relatively new cytostatic drug approved for the treatment of renal cell and hepatocellular carcinoma. In this report we describe the synthesis of sorafenib derivatives 4a–e which differ from sorafenib in their amide part. A 4-step synthetic pathway includes preparation of 4-chloropyri...

Descripción completa

Detalles Bibliográficos
Autores principales: Babić, Željka, Crkvenčić, Maja, Rajić, Zrinka, Mikecin, Ana-Matea, Kralj, Marijeta, Balzarini, Jan, Petrova, Mariya, Vanderleyden, Jos, Zorc, Branka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2012
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268433/
https://www.ncbi.nlm.nih.gov/pubmed/22269830
http://dx.doi.org/10.3390/molecules17011124

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6268433/
https://www.ncbi.nlm.nih.gov/pubmed/22269830
http://dx.doi.org/10.3390/molecules17011124

Ejemplares similares